Double-Masked Comparison of Ketorolac Tromethamine 0.4% Versus Nepafenac Sodium 0.1% for Postoperative Healing Rates and Pain Control in Eyes Undergoing Surface Ablation
Authors:
- William TrattlerWTWilliam Trattler
- Marguerite McDonaldMMMarguerite McDonald
- 1 July 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Cornea
- Vol. 26 (6) , 665-669
Abstract
Determine the degree of postoperative pain and rate of healing in eyes treated with either ketorolac tromethamine 0.4% (Acular LS) or nepafenac sodium 0.1% (Nevanac) after flapless surface ablation [epi-laser in situ keratomileusis (LASIK)]. Prospective, randomized, double-masked, paired-eye comparison. Patients undergoing flapless surface ablation were randomized to receive ketorolac in 1 eye and nepafenac in the other. Drops were instilled immediately after the surgical procedure, and patients continued to instill the masked drops 3 times daily for 5 days. Study follow-up visits were at days 1 and 5 postoperatively. Patients were queried by phone regarding their level of pain at 5 hours postoperatively and on days 2, 3, and 4. Outcome measures included postoperative pain levels including need for additional rescue medications, rate of healing, and adverse events. Although the original target population was 60 eyes of 30 patients, this study was halted after only 14 eyes of 7 patients because of concern for patient safety, because most patients in 1 arm developed haze. Eyes treated with nepafenac healed at a slower rate than eyes treated with ketorolac in 57% of patients. Mean time to healing was 5.7 +/- 1.1 days with ketorolac and 7.9 +/- 2.1 days with nepafenac (P = 0.066). Moreover, eyes treated with nepafenac exhibited statistically significant greater mean hazing scores at week 2 (P = 0.024) and month 1 (P = 0.039). Throughout the study, a greater percentage of nepafenac-treated eyes exhibited haze than did ketorolac-treated eyes. This difference was statistically significant at week 2 (P = 0.005) and month 1 (P = 0.039). Patients reported significantly more pain in nepafenac-treated eyes at day 3 when pain was at its peak (P = 0.046). In patients undergoing epi-LASIK, a statistically significant trend postoperative toward increased corneal haze was seen with nepafenac compared with ketorolac. Nepafenac therapy resulted in a non-statistically significant trend toward delayed healing. The study was halted because of safety concerns.Keywords
This publication has 15 references indexed in Scilit:
- Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: Pharmacokinetic-response curveJournal of Cataract & Refractive Surgery, 2006
- The Incidence of Endophthalmitis after Cataract Surgery among the U.S. Medicare Population Increased between 1994 and 2001Ophthalmology, 2005
- Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgeryCurrent Medical Research and Opinion, 2004
- Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patientsJournal of Cataract & Refractive Surgery, 2004
- Dynamic morphology of sutureless cataract wounds—effect of incision angle and locationSurvey of Ophthalmology, 2004
- Dynamic morphology of clear corneal cataract incisionsOphthalmology, 2003
- Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the corneaJournal of Cataract & Refractive Surgery, 2003
- Randomised controlled trial of ketorolac in the management of korneal abrasionsActa Ophthalmologica Scandinavica, 2001
- MOLECULAR AND CELLULAR RESPONSES OF THE CORNEAL EPITHELIUM TO WOUND HEALINGActa Ophthalmologica, 1992
- Effects of Steroidal and Non-Steroidal Anti-Inflammatory Agents on Corneal Wound HealingJournal of Ocular Pharmacology and Therapeutics, 1987